[NCI CIRB] S1905: A PHASE I/II STUDY OF AKR1C3-ACTIVATED PRODRUG OBI‐3424 (OBI-3424) IN PATIENTS WITH RELAPSED/REFRACTORY T‐CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) / T-CELL LYMPHOBLASTIC LYMPHOMA (T-LBL)
The purpose of this study is to determine if this approach to treating T-Cell Acute Lymphoblastic Leukemia or T-Cell Lymphoblastic Lymphoma is better or worse than the usual approach.
T-Cell Acute Lymphoblastic Leukemia
T-Cell Lymphoblastic Lymphoma
1- Diagnosis of relapsed or refractory T-ALL. Patient with relapsed T-Cell Lymphoblastic Lymphoma are eligible if lymphoblasts are >5% in the bone marrow or peripheral blood.
2- Patients must have evidence of acute leukemia in their peripheral blood or bone marrow, defined as >5% lymphoblast present. Patients with only intramedullary disease are not eligible.
3- Prior treatment must be complete within 14 days of study registration.
4- Prior nelarabine therapy is not required. However, patients that have received nelarabine during initial induction or post-remission treatment are eligible only if the physician does not feel they would benefit from other, multi-agent chemotherapy.
5- >18 years of age
6- Performace status of 0-3
18 - 99
Healthy Volunteers Needed
Duration of Participation
5 years after registration
Knight Information Line - email@example.com or 503-494-1080